Led · Series A · Jun 2026

Tripo AI develops AI 3D foundation models, world models, and a one-stop creative workspace for producing, editing, and rendering spatial content. Its recent model releases, Tripo H3.1 and Tripo P1.0 (March 2026), focus on high-precision geometry and production-ready meshes, and Tripo Studio includes features such as native 8K AI textures and Intelligent Part Segmentation V2. The company also runs an open-source initiative (projects released in 2024, 2025, and a third season) sharing components across the AI 3D stack, including collaborations with academic partners. With the nearly $200 million raised in its Series A+ and A++ financings, Tripo plans to expand research teams, accelerate algorithms, and bolster data and infrastructure to scale its product and ecosystem globally. It introduced Project Eden as a research effort to build persistent, editable, and multiplayer world models that separate world state from rendering to enable long-horizon persistence and concurrent interactions.

Led · Series A · Dec 2021

METiS Therapeutics integrates drug discovery and delivery using AI, machine learning and quantum simulation to develop optimized therapies for patients with serious diseases. Its proprietary AiTEM platform combines data-driven AI algorithms, mechanism-driven quantum mechanics and molecular dynamics simulations to calculate API properties, elucidate API-target and API-excipient interactions, and predict chemical, physical and pharmacokinetic properties in specific microenvironments. The platform is intended to enable efficient lead optimization, candidate selection and formulation design for small molecule and nucleic acid therapeutics. Founded by a team of MIT researchers, serial entrepreneurs and biotech industry veterans, METiS develops and in-licenses novel assets that could benefit from its data-driven platform. The company launched with an $86 million Series A financing led by PICC PE and China Life, with participation from Sequoia Capital China, Lightspeed, 5Y Capital, FreeS Fund and CMBI Zhaoxin Wuji Fund. METiS will use the financing to advance its pipeline of novel assets and continue development of its AI-driven drug discovery and delivery platform.

Participated · Series C · Sep 2020

XtalPi develops an ID4 (Intelligent Digital Drug Discovery and Development) platform that combines computational physics, quantum chemistry, and cloud computing to predict key characteristics of new drug candidates. The platform measures various chemical indicators to enhance drug R&D efficiency and has enabled hundreds of pharmaceutical companies to accelerate their research pipelines. According to the articles, ID4's work has led to dozens of discoveries. Financially, XtalPi completed a $400 million Series D in August 2021 led by OrbiMed and RRJ, following a $300 million Series C less than a year earlier. The Series D brought XtalPi's valuation to over RMB 13 billion (approximately USD 2 billion). XtalPi develops an AI‑powered platform that combines atomic‑level physics simulation with data science to predict and prioritize drug‑like molecules. The company works with major pharmaceutical partners, including Pfizer, to identify promising targets and reduce dead ends in R&D. Its technology emphasizes extremely low‑level simulation and prediction alongside more traditional machine‑learning approaches. XtalPi requires significant scientific staff and facilities to validate and advance digital predictions into real‑world candidates. The firm positions its platform as a way to improve research efficiency and success rates across drug discovery, though the broader field has not yet delivered prominent breakthroughs. XtalPi was founded in 2014 and is described as an American‑Chinese biotech operation. XtalPi develops computation-driven drug discovery and development applications that integrate quantum physics, artificial intelligence and cloud computing to predict important drug properties of small molecules. Its core products are computational tools intended to accelerate and de-risk pharmaceutical innovations. The company plans to use the new funds to support continuous market growth and expand application of its technology into new areas of pharmaceutical research. XtalPi was founded in 2014 by a group of quantum physicists at MIT and is based in Cambridge, Mass. To date it has raised over $66m. The business combines physics-driven models with AI to target pharmaceutical research workflows. XtalPi builds computational tools that predict the crystal structures of drug molecules to inform stability and other properties that affect clinical success. The company combines AI, quantum-physics algorithms and high-performance cloud computing to improve the efficiency and accuracy of drug design, and it also works on drug discovery. XtalPi has built an elastic HPC cloud that can deploy up to one million cores across AWS, Tencent Cloud, Google Cloud and Alibaba Cloud. Founded in 2014 by three Chinese MIT graduates, it operates offices in Cambridge, Beijing and Shenzhen and has about 60 employees. The company plans to use big data from its high-precision computing platform to develop new computational models and to expand into new segments of the pharma industry. It is also developing a "prediction-driven research lab" that will combine its computational R&D with lab technology to produce more precise results and predictions.

Led · Series C · May 2020

Novizan (南京诺唯赞生物科技有限公司), founded in 2012 and based in Nanjing, operates a technology platform that develops, produces and sells key raw materials and terminal reagents for life sciences, in vitro diagnostics (IVD) and biopharma. Its product set includes enzymes, antigens, antibodies and a range of diagnostic reagents across multiple product lines. The company emphasizes import substitution and claims domestic competitiveness across full product lines versus imported alternatives. During the COVID-19 pandemic Novizan developed SARS‑CoV‑2 nucleic acid test core materials and a SARS‑CoV‑2 IgM/IgG colloidal‑gold antibody test kit that received China Class III medical device registration and multiple overseas certifications. Management highlights strong R&D and commercialization capabilities and says the firm provides customized products and services to molecular diagnostics companies and research institutions. The company plans to continue industrializing core raw materials and reagents and to expand downstream into application areas that are currently import‑dominated.

Participated · Equity · Feb 2018

JD Logistics is the logistics arm of JD.com that became a standalone business last April. It operates seven fulfillment centers and 405 warehouses in China and supports fresh-produce logistics. The unit has tested drone delivery and plans to invest more heavily in logistics automation, including automated warehouses, drones and robotics. This funding is the division's first outside funding event. The infusion positions the unit to expand investments and pursue synergies in Southeast Asia, where JD.com has investments in Thailand, Indonesia and Vietnam. JD.com will remain the majority shareholder with an 81.4 percent stake and the transaction values JD Logistics at around $13.5 billion.